Rehman Farah, Rustin Gordon
Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK.
Expert Opin Investig Drugs. 2008 Oct;17(10):1547-51. doi: 10.1517/13543784.17.10.1547.
Interrupting tumour blood flow and delivery of nutrients to cause tumour death is the aim of antiangiogenic and vascular disrupting agents (VDAs). ASA404 is the first VDA to enter Phase III trials.
We review the preclinical and clinical data on this interesting agent and consider its place in modern therapeutics.
PubMed database was searched for 'ASA404', 'AS1404', 'DMXAA', 'vascular disrupting agents', 'ASA404 clinical trials', 'AS1404 clinical trials', 'DMXAA clinical trials'.
RESULTS/CONCLUSIONS: ASA404 is a tumour VDA that is well tolerated and has shown promise in the treatment of NSCLC in combination with paclitaxel and carboplatin. A confirmatory Phase III trial is currently ongoing.
阻断肿瘤血流和营养物质输送以导致肿瘤死亡是抗血管生成药物和血管破坏剂（VDAs）的目标。ASA404是首个进入III期试验的VDA。
我们回顾了关于这种有趣药物的临床前和临床数据，并探讨其在现代治疗中的地位。
在PubMed数据库中搜索“ASA404”“AS1404”“DMXAA”“血管破坏剂”“ASA404临床试验”“AS1404临床试验”“DMXAA临床试验”。
结果/结论：ASA404是一种肿瘤VDA，耐受性良好，与紫杉醇和卡铂联合用于治疗非小细胞肺癌（NSCLC）已显示出前景。目前正在进行一项验证性III期试验。
Zotero 插件